Latest news with #DaewoongPharmaceutical
Korea Herald
20 hours ago
- Business
- Korea Herald
Daewoong partners with Sweden's Salipro to boost drug discovery
Daewoong Pharmaceutical on Wednesday announced a strategic research partnership with Swedish biotech company Salipro Biotech to jointly develop next-generation therapeutics targeting membrane proteins. Under the agreement, Salipro will provide Daewoong access to its proprietary Salipro Platform, a technology that stabilizes membrane proteins in a near-native environment, making them more accessible for drug discovery. Membrane proteins are involved in essential cellular functions and account for over 60 percent of known drug targets, yet their structural instability in lab conditions has long been a barrier to research. The partnership is Salipro's first with a Korean company and follows previous collaborations with major pharmaceutical firms including Boehringer Ingelheim, Sanofi and Sumitomo. Daewoong views the alliance as a key step in its open innovation strategy, aiming to bolster its global competitiveness and lay the groundwork for potential overseas licensing deals. 'Our partnership with Daewoong marks Salipro's first collaboration with a Korean company, making it especially meaningful,' Jens Frauenfeld, CEO of Salipro Biotech, stated. 'The Salipro platform enables research on previously inaccessible target proteins and is expected to unlock new possibilities in global innovative drug development.' Park Seong-soo, CEO of Daewoong Pharmaceutical, added, 'We expect that the Salipro platform will enhance our access to challenging membrane protein targets and accelerate our drug discovery efforts. Through an open collaboration strategy, we will continue to develop globally competitive new drugs.'
Korea Herald
21 hours ago
- Business
- Korea Herald
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs. Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target. "We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical's pipeline", said Jens Frauenfeld, CEO of Salipro Biotech. "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable." Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts." About Salipro Biotech AB Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. About Daewoong Pharmaceutical Daewoong Pharmaceutical (KRX: established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product.
Yahoo
21 hours ago
- Business
- Yahoo
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs. Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target. "We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical's pipeline", said Jens Frauenfeld, CEO of Salipro Biotech. "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable." Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts." About Salipro Biotech ABSalipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. About Daewoong PharmaceuticalDaewoong Pharmaceutical (KRX: established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product. View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd.
Korea Herald
3 days ago
- Business
- Korea Herald
CGBio launches China joint venture to expand regenerative medicine reach
Korean regenerative medicine company CGBio, affiliated with Daewoong Pharmaceutical, announced Monday the establishment of Sol Cent Bio Co. Ltd., a joint venture with Chinese orthopedic device maker Shanghai Sanyou Medical, marking its full-scale entry into the Chinese regenerative medicine market. The new company will localize the production of advanced regenerative products and medical devices, including human tissue grafts and stem cell isolation systems, to meet China's growing clinical demand. Shanghai Sanyou Medical, a publicly listed company specializing in spinal and trauma care devices, brings strong manufacturing capabilities and a nationwide hospital network to the partnership. By combining CGBio's proprietary technologies with Sanyou's local expertise, Sol Cent Bio aims to accelerate regulatory approvals and build a stable supply chain within China. Initial offerings will include allogeneic bone grafts and acellular dermal matrices, widely used in bone regeneration, burn care and reconstructive surgery. The venture will also produce stem cell separation systems and other regenerative tools developed by CGBio and its subsidiary, CGMedtech. Through the joint venture, CGBio aims to expand its global footprint and deliver regenerative solutions tailored to Chinese patients and providers, while improving cost competitiveness under China's volume-based procurement system. 'The joint venture with Sanyou Medical marks a strategic shift, combining our technology with local manufacturing and sales strength,' said CGBio CEO Yu Hyun-seung. 'Local production will enhance supply stability and responsiveness, setting a new standard in Asia's regenerative medicine market.'
Korea Herald
7 days ago
- Business
- Korea Herald
Daewoong launches Nabota in Qatar, strengthens K-beauty in Middle East
Daewoong Pharmaceutical has officially launched its botulinum toxin product Nabota in Qatar, further strengthening its expansion into the Middle Eastern market, the company announced Thursday. The launch was marked by a symposium in Doha on May 30, where Nabota's entry into the Qatari market was formally announced. With this addition, Nabota is now available in all three key Gulf countries at the heart of the K-beauty trend: Qatar, Saudi Arabia and the United Arab Emirates. These nations represent high-potential markets, due to their high per capita income and growing interest in cosmetic and aesthetic procedures. Qatar, for example, had a per capita gross domestic product of around $80,000 in 2024, and demand for premium botulinum toxin products is rising quickly. According to Daewoong, the Qatar launch symposium attracted around 200 local medical professionals. 'Nabota is distinguished by its rapid and precise effects, making it the ideal product for Nabolift procedures that not only reduce wrinkles but also refine facial contours and expressions," Koo Bon-cheol, director of Naeum Dermatology and a featured speaker at the event, said. 'Given the limited number of botulinum toxin products currently registered in Qatar, the event highlighted the strong interest in Nabota among Middle Eastern health care providers,' Abdulkader Ramo, general practitioner from the UAE said. Meanwhile, Daewoong Pharmaceutical has also developed Nabolift, a proprietary technique that uses microinjections of botulinum toxin to promote lifting, reduce wrinkles and stimulate collagen production. The company plans to launch marketing campaigns across Qatar and the UAE that highlight differentiated procedures like the Nabolift, while strengthening its partnerships with local collaborators. 'The launch is meaningful in that it establishes Qatar as a new strategic foothold in the Middle East,' said Yoon Joon-soo, head of Daewoong's Nabota Business Division. 'We plan to further expand across the region by leveraging Nabota's high-quality performance and our exclusive treatment methods like Nabolift.'
